Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dna X (SONM) Gross Margin (2018 - 2025)

Historic Gross Margin for Dna X (SONM) over the last 8 years, with Q3 2025 value amounting to 11.2%.

  • Dna X's Gross Margin fell 169700.0% to 11.2% in Q3 2025 from the same period last year, while for Sep 2025 it was 18.33%, marking a year-over-year decrease of 85000.0%. This contributed to the annual value of 17.02% for FY2024, which is 36200.0% down from last year.
  • As of Q3 2025, Dna X's Gross Margin stood at 11.2%, which was down 169700.0% from 7.55% recorded in Q2 2025.
  • In the past 5 years, Dna X's Gross Margin ranged from a high of 49.97% in Q1 2025 and a low of 3.06% during Q4 2021
  • Its 5-year average for Gross Margin is 18.39%, with a median of 16.49% in 2023.
  • Its Gross Margin has fluctuated over the past 5 years, first plummeted by -393400bps in 2024, then surged by 326700bps in 2025.
  • Dna X's Gross Margin (Quarter) stood at 3.06% in 2021, then surged by 633bps to 16.3% in 2022, then soared by 134bps to 38.12% in 2023, then crashed by -103bps to 1.22% in 2024, then skyrocketed by 1017bps to 11.2% in 2025.
  • Its Gross Margin stands at 11.2% for Q3 2025, versus 7.55% for Q2 2025 and 49.97% for Q1 2025.